HPV-test, Cervical Cancer and Follow-up

NCT ID: NCT02096016

Last Updated: 2017-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators have planned this project to evaluate the follow-up program after surgery due to cervical cancer and to explore the possibilities for different tests of Human Papilloma Virus (HPV) in contributing to the customization of the follow-up program.

Purpose:

The investigators effort is to provide the background for an evidence-based update of the follow-up program after surgery due to cervical cancer with the purpose of early diagnosis of recurrence affecting quality of life for as few women as possible.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Papilloma Virus Uterine Cervical Neoplasms Recurrence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Human Papilloma Virus test

Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed.

It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study

Human Papilloma Virus test from the vaginal vault

Intervention Type PROCEDURE

Surveillance after surgical treatment of early stage cervical cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Human Papilloma Virus test from the vaginal vault

Surveillance after surgical treatment of early stage cervical cancer

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Surgery. FIGO stage IA-IB. \> 18 years

Exclusion Criteria

* Ajuvant oncologic treatment
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katrine Fuglsang, MD

Role: STUDY_DIRECTOR

Aarhus University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus University Hospital

Aarhus, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Katrine Fuglsang, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fuglsang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1-10-72-323-13

Identifier Type: -

Identifier Source: secondary_id

Follow-up

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.